skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Varlitinib (Code C62530)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Varlitinib

Definition: An orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. Varlitinib selectively and reversibly binds to both EGFR (ErbB-1) and Her-2/neu (ErbB-2) and prevents their phosphorylation and activation, which may result in inhibition of the associated signal transduction pathways, inhibition of cellular proliferation and cell death. EGFR and Her-2 play important roles in cell proliferation and differentiation and are upregulated in various human tumor cell types. Due to the dual inhibition of both EGFR and Her-2, this agent may be therapeutically more effective than agents that inhibit EGFR or Her-2 alone.

Display Name: Varlitinib

Label: Varlitinib

NCI Thesaurus Code: C62530 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831861  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

External Source Codes: 
CAS Registry Number 845272-21-1 (see NLM ChemIDplus info)
FDA UNII Code 846Y8197W1
PDQ Closed Trial Search ID 487532
PDQ Open Trial Search ID 487532 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831861

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C22H19ClN6O2S
code C62530
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name ARRY-334543
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom